Engineered immune cells take on Hard-to-Treat myeloma

NCT ID NCT05976555

Recruiting now Disease control Sponsor: Medical College of Wisconsin Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 11, 2026 · Updated 2 times

Summary

This early-phase study tests a new kind of CAR T-cell therapy for people with multiple myeloma that has come back or not responded to at least three prior treatments. The cells are 'armored' to resist a protein (TGF-beta) that normally blocks their attack. Up to 30 adults will receive one of four dose levels to find the safest dose and check for side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: BCMA-TGFβ CAR-T cells
What this could lead to: If successful, this could lead to a more effective treatment for multiple myeloma that has stopped responding to other therapies.
What could go wrong: This is an early phase 1 trial with only 30 people, so it is too soon to know if it works. There are risks of serious side effects like cytokine release syndrome.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA

Contacts and locations

Locations

Froedtert & the Medical College of Wisconsin
RECRUITING

Milwaukee, Wisconsin, 53226, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.